Avascular necrosis is a disease that results from the short-term or permanent loss of blood supply to the bone. This cut-off of blood supply to bone leads to tiny breaks in the bone and the bones eventually collapse. Avascular necrosis is also known as osteonecrosis. This condition may happen in any bone of the body, but mostly happens in the ends of a long bone. A broken bone or dislocated joint can interrupt the blood flow to a section of bone. Avascular necrosis condition is most common in people between the ages of 30 and 50.
Avascular necrosis can be caused due to-
- Injury to bone
- Fracture
- Damage of blood vessels
- Long-term use of medicines, such as corticosteroids
- Excessive, long-term use of alcohol
Avascular necrosis can be diagnosed by Bone scan, Magnetic Resonance Image and Computed Tomography, and X-rays. Medications used to treat avascular necrosis are blood thinners, nonsteroidal anti-inflammatory drugs, cholesterol lowering drugs and others.
Increasing number of product launches is expected to drive the growth of global avascular necrosis market during the forecast period. For instance, in September 2014, Bayer Healthcare LLC, a pharmaceutical and medicine manufacturing company, announced the launch of Aleve PM, an over-the-counter (OTC) pain reliever product in the U.S.
Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global avascular necrosis market. For instance, in April 2019, the U.S Food and Drugs Administration approved Evenity (romosozumab-aqqg), a sclerostin inhibitor indicated to treat osteoporosis in postmenopausal women at high risk of breaking a bone.
- This report provides an in-depth analysis of the global avascular necrosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global avascular necrosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Solara Active Pharma Sciences Limited., Bayer AG, Rochem International, Inc., Alkem Labs., Dwarkesh Pharmaceuticals Private Limited., Novartis AG, GSK, and Pfizer Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global avascular necrosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global avascular necrosis market
-
- Nonsteroidal anti-inflammatory drugs (Ibuprofen, Naproxen Sodium)
- Osteoporosis Drugs
- Cholesterol-lowering Drugs
- Blood Thinners
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- South Africa
- Central Africa
-
- Teva Pharmaceutical Industries Ltd.
- Reddy’s Laboratories Ltd.
- Solara Active Pharma Sciences Limited
- Bayer AG
- Rochem International Inc.
- Alkem labs.
- Dwarkesh Pharmaceuticals Private Limited.
- Novartis AG
- GSK
- Pfizer, Inc.
